There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor
alpha, is an established treatment for Crohn's disease but not ulcerative colitis.